TORONTO and HAIFA, Israel, Jan. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (NRX:CA), (OTCQB: NRXBF), (Germany: J90) ("NurExone" or the "Company"), a developer of exosome-based therapies for ...
BELTSVILLE, Md., March 3, 2026 /PRNewswire/ -- REPROCELL (TYO: 4978) today announced the launch of its US FDA compliant Good Manufacturing Practice (GMP) Master Cell Bank (MCB) manufacturing service ...
FibroBiologics, Inc. has announced the completion of its proprietary master cell bank, which will support its upcoming clinical trials. Developed in partnership with Charles River Laboratories and ...
Singapore General Hospital (SGH) has entered into an agreement with pharmaceutical company Charles River Laboratories to ...